Dyne Therapeutics Inc at Jefferies CNS & Neuro Summit Transcript
All right, well, thank you, everyone who's here and joining us virtually as well. My name is Mack Chandler. I'm with Jefferies Research. I'm joined by Dyne Therapeutics here. We have Oxana Beskrovnaya, the Chief Science Officer; Wildon Farwell, the Chief Medical Officer; and Rob Lauzen, the Vice President of Investor Relations and Head of FP&A.
Questions & Answers
So thank you all for joining us today. We're very excited about the upcoming data that Dyne will present here shortly. Before we get into some of the programs and our expectations or your expectations for them, Wildon or Oxana, would mind just giving us a quick overview of the FORCE platform and the rationale behind the design of DYNE-101 and DYNE-101?
Thank you for your question. DYNE was designed with one question to solve. It's enable delivery of powerful therapeutics such as oligonucleotides
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |